A detailed history of Vanguard Group Inc transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Vanguard Group Inc holds 7,022,095 shares of ABUS stock, worth $27.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,022,095
Previous 5,987,907 17.27%
Holding current value
$27.2 Million
Previous $15.4 Million 40.46%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$2.52 - $3.63 $2.61 Million - $3.75 Million
1,034,188 Added 17.27%
7,022,095 $21.7 Million
Q1 2024

May 10, 2024

SELL
$2.26 - $2.92 $2,205 - $2,849
-976 Reduced 0.02%
5,987,907 $15.4 Million
Q4 2023

Feb 14, 2024

BUY
$1.69 - $2.54 $69,055 - $103,786
40,861 Added 0.69%
5,988,883 $15 Million
Q3 2023

Nov 14, 2023

BUY
$1.9 - $2.27 $244,469 - $292,076
128,668 Added 2.21%
5,948,022 $12.1 Million
Q2 2023

Aug 14, 2023

BUY
$2.24 - $3.06 $399,060 - $545,145
178,152 Added 3.16%
5,819,354 $13.4 Million
Q1 2023

May 15, 2023

BUY
$2.23 - $3.1 $615,874 - $856,148
276,177 Added 5.15%
5,641,202 $17.1 Million
Q4 2022

Feb 10, 2023

BUY
$1.91 - $2.85 $189,359 - $282,551
99,141 Added 1.88%
5,365,025 $12.5 Million
Q3 2022

Nov 14, 2022

BUY
$1.88 - $2.88 $121,231 - $185,716
64,485 Added 1.24%
5,265,884 $10.1 Million
Q2 2022

Aug 12, 2022

BUY
$1.98 - $3.17 $917,177 - $1.47 Million
463,221 Added 9.78%
5,201,399 $14.1 Million
Q1 2022

May 13, 2022

BUY
$2.42 - $3.98 $442,095 - $727,082
182,684 Added 4.01%
4,738,178 $14.1 Million
Q4 2021

Feb 14, 2022

BUY
$3.11 - $4.61 $2.46 Million - $3.64 Million
789,515 Added 20.96%
4,555,494 $17.7 Million
Q3 2021

Nov 12, 2021

BUY
$2.65 - $4.62 $78,826 - $137,426
29,746 Added 0.8%
3,765,979 $16.2 Million
Q2 2021

Aug 13, 2021

BUY
$2.5 - $3.51 $9.34 Million - $13.1 Million
3,736,233 New
3,736,233 $11.3 Million

Others Institutions Holding ABUS

About Arbutus Biopharma Corp


  • Ticker ABUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,951,008
  • Market Cap $580M
  • Description
  • Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...
More about ABUS
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.